Health
IMV Provides Updates On COVID-19 Vaccine Program – Press Release – Digital Journal
“We are advancing DPX-COVID-19 on the strength of its novel mechanism of action and potential for rapid scale-up manufacturing. We greatly appreciate the recogn…
DARTMOUTH, Nova Scotia–(Business Wire)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on its vaccine candidate, DPX-COVID-19, for the prevention of infection caused by the novel coronavirus SARS-COV-2.
We are advancing DPX-COVID-19 on the strength of its novel mechanism of action and potential for rapid scale-up manufacturing. We greatly appreciate …
-
Noosa News19 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business20 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News22 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Business23 hours agoDividends from ASX 200 bank shares ‘looking very stretched’: expert